Alembic Straddles Oversupply And Shortages In US
One-off opportunities lift Alembic’s US generics business in the fiscal second quarter but the market continues to pose challenges amid surging oversupply and price erosion. On the other hand, a string of injectable approvals, including for ketorolac tromethamine, could open up opportunities for the company given the 'on and off' shortages.
You may also be interested in...
Strides has agreed to partner with Orbicular to develop four nasal sprays targeting a combined market worth more than $400m for markets including Europe and the US.
Generic Revlimid, lanreotide propel Cipla’s US business to a high in the fiscal second quarter, with products like leuprolide depot set for debut ‘any time now’. Management signals cost edge for generic Advair as it awaits further word following a FDA establishment inspection report at its Indian site, while a Plan B is being initiated for generic Abraxane.
Lupin has acquired all US market rights to Sunovion’s Brovana and Xopenex HFA branded inhalation products for $75m, strengthening its presence in the US respiratory market.